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T
 
he concept of immune privilege refers to the observa-
tion that tissue grafts placed in certain anatomical sites,
including the brain and eye, can survive for extended peri-
 
ods of time (1). Immune privilege is thought to reflect an
 
evolutionary adaptation to protect vital structures from dam-
age by inflammatory responses directed against pathogens.
It was originally believed that antigens in immune-privi-
leged sites are concealed from the immune system by phys-
ical barriers and therefore ignored. However, subsequent
 
studies have shown that antigens do leave immune-privileged
sites, that these antigens can induce immune responses, and
that immune effector cells can have access to immune-priv-
ileged sites. It is now clear that immune privilege is main-
tained by an active rather than passive process (2–4).
 
The eye is an excellent example of an immune-privileged
site. This organ enjoys immune privilege to protect it from
destructive inflammation that may impair vision. Immune
privilege in the eye is attributed to a variety of mechanisms
(for reviews, see references 2–4), including lack of lymphatic
drainage, low expression of MHC molecules, increased ex-
pression of surface molecules (CD59, membrane cofactor
protein, and decay-accelerating factor) that inhibit comple-
ment activation, local production of immunosuppressive cy-
 
tokines such as TGF-
 
b
 
, presence of neuropeptides, and
constitutive expression of Fas ligand (FasL). The latter mech-
anism controls the entry of Fas-expressing lymphoid cells
into the eye (5). Additionally, antigen presentation in the
eye can elicit regulatory T (Tr) cells that induce immune
deviation and suppress inflammatory responses, both locally
and systemically (for a review, see reference 2). In this is-
sue, Sonoda et al. (6) demonstrate that immune deviation
induced by antigens placed in the anterior chamber (AC) of
the eye requires CD1d-reactive natural killer T (NKT)
cells. These findings provide insights into the maintenance
of immune privilege and indicate that NKT cells play a
critical role in the regulation of immune responses.
 
AC-associated Immune Deviation
 
It is well established that injection of antigens into the
AC of the eye results in a form of immune deviation termed
AC-associated immune deviation (ACAID; for a review,
see reference 2). This phenomenon was first identified by
Kaplan and Streilein (7), who reported that injection of F1
lymphoid cells into the AC of rat eyes alters the recipient’s
systemic immune response such that rejection of subse-
quent allografts from the donor strain used for AC priming
is impaired. Since then, ACAID has been demonstrated for
several antigens, including viruses, corneal allografts, and
tumor cells. The hallmarks of ACAID are suppression of
delayed-type hypersensitivity (DTH) and inhibition of the
synthesis of complement-fixing antibody isotypes.
Antigen introduced into the AC is captured by special-
ized APCs of the eye that carry the antigen via the blood to
the spleen. A deviant form of immunity is then generated
which is capable of suppressing Th1-mediated DTH re-
sponses and production of complement-fixing antibodies.
 
CD8
 
1
 
 T cells isolated from the spleen of AC-immunized
mice can induce ACAID and inhibit DTH responses when
transferred into naive syngeneic mice (8). These findings
strongly indicate that AC immunization results in the in-
duction of CD8
 
1
 
 Tr cells that inhibit Th1 cells (see Fig. 1).
Interestingly, since ACAID in this system is induced by
 
soluble antigen, presentation of antigen to CD8
 
1
 
 Tr cells
must follow the poorly characterized exogenous pathway
of MHC class I–restricted antigen presentation (4).
There is considerable evidence that the immunosuppres-
sive cytokine TGF-
 
b
 
 plays a critical role in the induction
and/or effector function of CD8
 
1
 
 Tr cells during ACAID
(2). For example, AC injection of antigen induces the gen-
eration of T cells in the spleen that produce TGF-
 
b
 
 when
stimulated with antigen in vitro. Studies by Griffith et al.
(9) further indicated that immune tolerance after antigen
injection in the eye depends on the death of lymphoid cells
by the Fas/FasL system. Although the exact mechanism by
which apoptosis of lymphoid cells affects ACAID remains
unclear, it was suggested that apoptotic lymphoid cells pro-
duce IL-10 which, in turn, induces immune deviation by its
effects on APCs (10). The paper from Sonoda et al. (6) pro-
vides another piece to this puzzle, demonstrating that NKT
cells are required for the induction of CD8
 
1
 
 Tr cells.
 
NKT Cells
 
NKT cells represent a relatively novel lymphocyte subset
distinct from conventional T cells, B cells, and NK cells.
NKT cells share receptor structures with both NK cells and
 
conventional T cells (for reviews, see references 11, 12). NKT
 
cells express typical NK cell markers, including IL-2R
 
b
 
,
members of the NKR-P1 NK cell–activating receptor fam-
ily, and members of the Ly49 NK cell–inhibitory receptor
family. They also express a TCR with an invariant V
 
a
 
14-
J
 
a
 
281 chain and a polyclonal V
 
b
 
8.2 (and to a lower extent,
V
 
b
 
7 or V
 
b
 
2) chain. Approximately 60% of all NKT cells 
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express CD4, and the remaining cells do not express either
CD4 or CD8. These cells have a memory phenotype, ex-
pressing high levels of the early activation marker CD69,
high levels of CD44 (Pgp-1), and low levels of CD62L
(L-selectin). NKT cells are abundant in the thymus and
represent a major population of lymphocytes in the spleen,
bone marrow, and liver, but are rare in lymph nodes.
Unlike conventional T cells that recognize peptide anti-
gens in the context of self-MHC class I or class II mole-
cules, NKT cells are specific for glycolipid antigens bound
with the MHC class I–like molecule, CD1d (for reviews,
see references 11, 12). As CD1d expression is required for
the development of NKT cells, CD1d-deficient mice have
a marked reduction in the number of NKT cells (13–15).
Autoreactivity appears to be common among NKT cells.
Many NKT cell hybridomas were able to react with sple-
nocytes, thymocytes, or CD1d-transfected cells (11). Inter-
estingly, individual hybridomas differed in their reactivity
with CD1d-expressing cells, suggesting substantial hetero-
geneity among NKT cells (16, 17). Recent studies have
shown that CD1d can bind with a variety of glycolipids,
including phosphatidylinositol derivatives (18, 19) and gly-
cosylceramides (20). However, the physiological signifi-
cance of these glycolipids for NKT cell function is unclear.
When activated through their TCR, NKT cells become
cytotoxic and quickly produce a variety of cytokines, in-
cluding large amounts of IL-4, significant amounts of IFN-
 
g
 
,
and some inhibitory cytokines such as TGF-
 
b
 
 and IL-10
(11, 21). Although their physiological functions remain un-
clear, NKT cells have been implicated in immune responses
against infectious agents, bone marrow grafts, tumors, and
self-antigens (11, 12).
 
Role of NKT Cells in the Development of ACAID
 
The paper by Sonoda et al. (6) provides convincing evi-
dence that NKT cells are required for development of
ACAID. AC administration of antigen to NKT cell–defi-
cient CD1d knockout mice did not induce ACAID, unless
these animals were reconstituted with NKT cells from wild-
type mice together with CD1d-expressing APCs. Since
anti-CD1d antibodies inhibited development of ACAID in
wild-type animals, direct interaction of the invariant V
 
a
 
14
TCR with CD1d appears to be required. The question
then arises as to what NKT cells recognize in the spleen
after AC administration of protein antigen. One possibility
is that eye APCs express, as a result of exposure to immu-
nosuppressive cytokines such as TGF-
 
b
 
, high levels of
CD1d that activate autoreactive NKT cells. Alternatively,
introduction of antigen into the AC may cause expression
of specific endogenous glycolipids that activate NKT cells.
At what step do NKT cells contribute to the induction
of ACAID? Prior studies have shown that CD8
 
1
 
 T cells
from the spleen of AC-primed mice can adoptively transfer
ACAID to naive animals (8). The studies of Sonoda et al. (6)
further extend these findings by demonstrating that NKT
cell–depleted spleen cell populations from AC-primed ani-
mals can inhibit DTH reactions after adoptive transfer to
naive animals. Therefore, these findings indicate that NKT
cells are specifically required for the generation of antigen-
specific CD8
 
1
 
 Tr cells.
A likely scenario for the induction of ACAID, based on
the findings of Sonoda et al. (6), is presented in Fig. 1. An-
tigen inoculated into the AC of the eye is captured by spe-
cialized APCs that carry the antigen to the spleen. These
Figure 1. Model for the role of NKT cells in the induction of immune
deviation after inoculation of antigen into the eye. Antigen injected into
the eye is captured by eye APCs that carry the antigen to the spleen.
These eye APCs activate NKT cells which, in turn, produce cytokines
such as TGF-b that induce the generation and expansion of antigen-spe-
cific MHC class I–restricted CD81 Tr cells. These CD81 Tr cells, by
production of cytokines such as TGF-b and IL-10, can downregulate
subsequent Th1-mediated DTH reactions against the same antigen. Note
that presentation of antigen to CD81 Tr cells in this system follows the
exogenous pathway of MHC class I–restricted antigen presentation,
which is poorly understood. 
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eye APCs may have unique features that are critically im-
portant for the induction of ACAID, including increased
expression of CD1d (perhaps induced by TGF-
 
b
 
 in the
AC) and altered antigen-presenting properties (perhaps in
response to IL-10 produced by apoptotic lymphoid cells).
These eye APCs then activate effector T cells, CD8
 
1
 
 Tr
cells, and NKT cells. Activated NKT cells produce cyto-
kines (TGF-
 
b
 
 is a likely candidate) that stimulate the gen-
eration and expansion of antigen-specific CD8
 
1
 
 Tr cells. In
turn, these CD8
 
1
 
 Tr cells can inhibit, by production of cy-
tokines (TGF-
 
b
 
 and IL-10 are likely candidates), subse-
quent Th1-mediated DTH responses to the same antigen.
 
Implications
 
There is now compelling evidence that Tr cells partici-
pate in many immune responses, including responses against
foreign and self-antigens (22). The findings of Sonoda et al.
(6) raise the possibility that activation of NKT cells is a
general mechanism for the generation of Tr cells. Prior
studies have suggested a role for NKT cells in the regula-
tion of immune responses. Various mouse strains with ge-
netic susceptibility for the development of autoimmune
disease, including nonobese diabetic (NOD) mice with a
propensity for development of type I diabetes, SJL mice
with a susceptibility for development of experimental aller-
gic encephalomyelitis, and several lupus-prone strains, were
found to have defects in NKT cell development and/or
function (23–26). Reconstitution of NOD mice with NKT
cells (27) or transgenic overexpression of NKT cells in
these animals (28) was able to inhibit development of dia-
betes. Further, NKT cells isolated from V
 
a
 
14-J
 
a
 
281 trans-
genic mice either induced or prevented murine lupus in an
adoptive transfer model (29), depending on the source and
cytokine profiles of the NKT cells that were transferred.
Defects in NKT cell development and function were also
observed in human patients with systemic sclerosis (30) and
in patients with type I diabetes (31). In addition to their
role in the regulation of autoimmunity, NKT cells were
shown to influence immune responses against tumors (21)
and infectious agents (19, 32–34), and to suppress graft ver-
sus host disease (35). In many of these studies it was sug-
gested that NKT cells influence the disease process by pro-
duction of cytokines. For example, the inhibitory role of
NKT cells for the development of Th1-dominated inflam-
mation in several autoimmune diseases was attributed to
their production of IL-4, which promotes Th2 immunity.
An alternative explanation, not excluded by these studies
and supported by the findings of Sonoda et al. (6), is that
NKT cells induce the generation of Tr cells that, in turn,
inhibit inflammation.
It is unlikely that NKT cells participate in all types of im-
mune regulation controlled by Tr cells. Indeed, Sonoda et al.
(6) showed that NKT cells are dispensable for the systemic
tolerance induced in response to intravenous injection of
antigen. Perhaps other cell types, such as 
 
g
 
/
 
d
 
 T cells and
NK cells, can contribute to the regulation of immune re-
sponses and induction of self-tolerance. A role for 
 
g
 
/
 
d
 
 T
cells as regulators of immune responses has been suggested
(for a review, see reference 22).
The realization that NKT cells play a critical role in im-
mune regulation and maintenance of self-tolerance raises the
possibility of manipulating these cells to modulate immune
responses during prophylaxis and therapy. This should be
possible with reagents such as the glycolipid 
 
a
 
-galactosylcer-
amide that selectively activates NKT cells (20). Recent
studies have shown that administration of this agent to mice
can polarize adaptive immune responses towards Th2-domi-
nated immunity (36, 37).
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